Sanofi/Regeneron Dupixent helps improve esophagus inflammatory condition in kids in phase 3 trial
Dr_Microbe

Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) said their medicine Dupixent helped reduce disease severity and met the main goal of a phase 3 trial in children aged one to 11 years with eosinophilic esophagitis (EoE).
EoE is a chronic inflammatory disease in which a type of white blood cell called eosinophil builds up in the lining of the esophagus. This build up damages the esophagus and can cause symptoms including acid reflux, vomiting, abdominal discomfort and trouble in swallowing.
The study, included 102 children aged one to 11 who received Dupixent in either a higher dose (n=37) or lower dose (n=31) based on body weight or placebo (n=34).
At 16 weeks, 68% of children on higher dose and 58% of patients on lower dose Dupixent achieved the main goal of significant histological disease remission, compared to 3% of children on placebo, according to the companies' July 14 press release.
In addition, at week-16 children receiving higher dose of Dupixent showed an 86% reduction in peak esophageal intraepithelial eosinophil count from baseline compared to a 21% increase for placebo.
The companies added that the safety of the drug was generally consistent with the known safety profile of Dupixent in its approved EoE indication.
In May, Dupixent was approved to treat patients with EoE aged 12 years and older who weigh at least 40 kg.
Dupixent â which is approved for certain patients with atopic dermatitis, asthma, CRSwNP or eosinophilic esophagitis â generated $1.81B in sales in Q1, according to Regeneron.